No approved therapy exists for a pathogen responsible for 685 million infections and 200,000 deaths annually — and that gap is precisely what makes Cocrystal Pharma’s CDI-988 worth watching closely right now. The compound, an oral direct-acting 3CL protease inhibitor, has moved into a Phase 1b human challenge study at Emory University, with the first cohort — up to 40 healthy adults aged 18–49 — now fully enrolled for the infectivity-validation stage using the GII.2 Snow Mountain Virus inoculum.
The challenge model design is the strategically intelligent choice here. Rather than running a conventional field efficacy trial against a pathogen with unpredictable outbreak timing and no validated surrogate endpoint, Cocrystal opted for a controlled human infection framework that collapses proof-of-concept timelines and tests two distinct use cases — prophylaxis and treatment — within a single study architecture. Prevention and treatment cohorts follow the infectivity stage, with CDI-988 dosed at 1,200 mg twice daily for five days. Primary endpoint is reduction in clinical symptom incidence; secondary endpoints cover viral shedding and disease severity. That dual-indication design is deliberate: norovirus outbreaks are short and explosive, meaning any viable drug needs to work both before and after exposure.
The mechanistic rationale for CDI-988 is also stronger than typical antiviral pitch decks suggest. Vaccine programs have repeatedly failed to clear regulatory thresholds partly because norovirus spans 10 genogroups and 49 genotypes, with constant antigenic drift. CDI-988 targets the highly conserved 3CL protease active site — the same catalytic machinery found across all known norovirus strains and, notably, all coronaviruses. Gastrointestinal-targeted pharmacokinetics concentrate the drug at the actual site of replication, and the Phase 1 ascending-dose study in healthy adults showed tolerability up to 1,200 mg with no serious adverse events, supporting the dose selected for Phase 1b.
The infectivity cohort result is the pivot point. If GII.2 Snow Mountain Virus achieves adequate infection rates in the control arm, the prevention and treatment cohorts proceed on solid statistical footing. If infectivity is low or inconsistent, the entire proof-of-concept framework stalls regardless of CDI-988’s antiviral activity. That infectivity readout — not the drug data itself — is the immediate result to watch.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
